Endocrine Abstracts

Midgut Carcinoid disease (MGC) is uncommon, occurring in approximately 1.4 per 100,000 of the population per year. MGC has an unpredictable disease progression varying from rapid and aggressive to slow and indolent. For this reason it is not appropriate to treat all patients according to the same schedule. As some treatments are not without risk, it is important to identify those patients selected for these options at an appropriate stage of disease.In a...

Glucagon-like peptide-1 receptor (GLP-1R) agonists are effective treatments for type 2 diabetes and obesity. We recently described ‘biased’ peptide GLP-1R agonists modelled on exendin-4 which uncouple the pronounced endocytosis that usually accompanies GLP-1R activation, leading to prolongation of intracellular signalling responses. Here, we show that the metabolic consequences of biased GLP-1R activation in vivo are dominated by improvements in blood glucos...